9 Potential Blockbuster Drugs to be Approved in 2022
Donanemab (Lilly), Tirzepatide (Lilly), Gantenerumab (Roche), Deucravacitinib (Bristol Myers Squibb), Bardoxolone (Reata), Vutrisiran (Alnylam), Mavacamten (Bristol-Myers Squibb), Cilta-cel (Johnson & Johnson/ Legendary Biologics) and Adagrasib (Mirati Therapeutics) are 9 potential blockbuster drugs to be approved in 2022.
-
Follow
-
0
-
Embed
-
Share
-
Upload
